Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous cluster immunotherapy for Olea europaea pollen allergy
2024-511383-88-00Phase 3Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Jul 2024
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of CLU-RX-OLE in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and olive pollen allergy (4 arms), sponsored by ROXALL Medizin GmbH. Primary endpoint: Absolute difference in mean Combined Symptom and Medication Score (CSMS) during Peak Olive Pollen Period (POPP). Started Jul 2024; status: completed.
02
Drugs
CLU-RX-OLE
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)olive pollen allergy
Beyond the preview
Go deeper on 2024-511383-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511383-88-00.